Su, C., Chai, H., See, Y., & Kumar, R. S. (2024). GLYCEMIC CONTROL AND BODY WEIGHT EFFECTS OF SGLT2 INHIBITORS (EMPAGLIFLOZIN 25 MG, EMPAGLIFLOZIN 12.5 MG AND DAPAGLIFLOZIN 10 MG) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: A SINGLE CENTRE STUDY. Journal of the ASEAN Federation of Endocrine Societies, 39(S1), 25. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/4457